IL305873A - Extracellular vesicle compositions - Google Patents
Extracellular vesicle compositionsInfo
- Publication number
- IL305873A IL305873A IL305873A IL30587323A IL305873A IL 305873 A IL305873 A IL 305873A IL 305873 A IL305873 A IL 305873A IL 30587323 A IL30587323 A IL 30587323A IL 305873 A IL305873 A IL 305873A
- Authority
- IL
- Israel
- Prior art keywords
- extracellular vesicle
- vesicle compositions
- compositions
- extracellular
- vesicle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163169751P | 2021-04-01 | 2021-04-01 | |
PCT/US2022/023120 WO2022212884A1 (en) | 2021-04-01 | 2022-04-01 | Extracellular vesicle compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
IL305873A true IL305873A (en) | 2023-11-01 |
Family
ID=81384799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL305873A IL305873A (en) | 2021-04-01 | 2022-04-01 | Extracellular vesicle compositions |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240209368A1 (en) |
EP (1) | EP4304566A1 (en) |
JP (1) | JP2024513841A (en) |
KR (1) | KR20230166101A (en) |
CN (1) | CN117120041A (en) |
CA (1) | CA3213989A1 (en) |
IL (1) | IL305873A (en) |
WO (1) | WO2022212884A1 (en) |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
CA2361318C (en) | 1999-02-12 | 2008-11-25 | Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
DE602007009487D1 (en) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE |
US20090292006A1 (en) | 2006-05-05 | 2009-11-26 | Sanjay Bhanot | Compounds and methods for modulating expression of dgat2 |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
ES2386492T3 (en) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2013036868A1 (en) | 2011-09-07 | 2013-03-14 | Marina Biotech Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
EP3672573A4 (en) | 2017-08-25 | 2021-05-26 | Codiak BioSciences, Inc. | Preparation of therapeutic exosomes using membrane proteins |
CN111511384A (en) | 2017-11-17 | 2020-08-07 | 科迪亚克生物科学公司 | Compositions of engineered exosomes and methods of loading luminal exosome payloads |
ES2907967T3 (en) | 2018-11-16 | 2022-04-27 | Codiak Biosciences Inc | Modified extracellular vesicles and their uses |
WO2021030776A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
WO2021062317A1 (en) * | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Extracellular vesicle compositions |
-
2022
- 2022-04-01 WO PCT/US2022/023120 patent/WO2022212884A1/en active Application Filing
- 2022-04-01 KR KR1020237036543A patent/KR20230166101A/en unknown
- 2022-04-01 EP EP22718481.9A patent/EP4304566A1/en active Pending
- 2022-04-01 CN CN202280026972.0A patent/CN117120041A/en active Pending
- 2022-04-01 JP JP2023560441A patent/JP2024513841A/en active Pending
- 2022-04-01 CA CA3213989A patent/CA3213989A1/en active Pending
- 2022-04-01 IL IL305873A patent/IL305873A/en unknown
- 2022-04-01 US US18/552,778 patent/US20240209368A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230166101A (en) | 2023-12-06 |
JP2024513841A (en) | 2024-03-27 |
CA3213989A1 (en) | 2022-10-06 |
CN117120041A (en) | 2023-11-24 |
EP4304566A1 (en) | 2024-01-17 |
WO2022212884A1 (en) | 2022-10-06 |
US20240209368A1 (en) | 2024-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291690A (en) | Extracellular vesicle compositions | |
IL286260A (en) | Plant-derived extracellular vesicle (evs) compositions and uses thereof | |
IL286562A (en) | Extracellular vesicle conjugates and uses thereof | |
GB202013432D0 (en) | Compositions | |
EP3705566A4 (en) | Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles | |
GB201915855D0 (en) | An extracellular vesicle | |
GB202015836D0 (en) | Compositions | |
IL305873A (en) | Extracellular vesicle compositions | |
GB202105461D0 (en) | Compositions | |
GB202102704D0 (en) | Compositions | |
GB202019952D0 (en) | Novel compositions | |
GB202017863D0 (en) | Novel compositions | |
GB202011581D0 (en) | Anti-microbial compositions | |
GB201910450D0 (en) | Cosmetic compositions | |
GB2601997B (en) | Extracellular vesicle characterization systems | |
ZA202210764B (en) | Compositions | |
IL312478A (en) | Das181 variant compositions | |
GB202208611D0 (en) | Compositions | |
GB202012160D0 (en) | New compositions | |
GB202118081D0 (en) | Compositions | |
GB202117074D0 (en) | Compositions | |
GB202116861D0 (en) | Compositions | |
GB202116388D0 (en) | Compositions | |
GB202116386D0 (en) | Compositions | |
GB202115617D0 (en) | Compositions |